| ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers J Garousi, S Lindbo, J Nilvebrant, M Åstrand, J Buijs, M Sandström, ... Cancer research 75 (20), 4364-4371, 2015 | 81 | 2015 |
| Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer O Bragina, E von Witting, J Garousi, R Zelchan, M Sandström, A Orlova, ... Journal of nuclear medicine 62 (4), 493-499, 2021 | 75 | 2021 |
| Influence of histidine-containing tags on the biodistribution of ADAPT scaffold proteins S Lindbo, J Garousi, M Åstrand, H Honarvar, A Orlova, S Hober, ... Bioconjugate chemistry 27 (3), 716-726, 2016 | 55 | 2016 |
| Quantum dot–based FRET immunoassay for HER2 using ultrasmall affinity proteins YT Wu, X Qiu, S Lindbo, K Susumu, IL Medintz, S Hober, N Hildebrandt Small 14 (35), 1802266, 2018 | 44 | 2018 |
| Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label S Lindbo, J Garousi, B Mitran, M Altai, J Buijs, A Orlova, S Hober, ... Journal of Nuclear Medicine 59 (1), 93-99, 2018 | 42 | 2018 |
| Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours J Garousi, S Lindbo, J Borin, E von Witting, A Vorobyeva, M Oroujeni, ... European journal of pharmaceutics and biopharmaceutics 134, 37-48, 2019 | 32 | 2019 |
| Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 E von Witting, J Garousi, S Lindbo, A Vorobyeva, M Altai, M Oroujeni, ... European journal of pharmaceutics and biopharmaceutics 140, 109-120, 2019 | 28 | 2019 |
| Bispecific applications of non-immunoglobulin scaffold binders S Hober, S Lindbo, J Nilvebrant Methods 154, 143-152, 2019 | 28 | 2019 |
| Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m J Garousi, S Lindbo, B Mitran, J Buijs, A Vorobyeva, A Orlova, ... Scientific reports 7 (1), 14780, 2017 | 24 | 2017 |
| Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga S Lindbo, J Garousi, B Mitran, A Vorobyeva, M Oroujeni, A Orlova, ... Molecular Pharmaceutics 15 (7), 2674-2683, 2018 | 17 | 2018 |
| Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A H Liu, S Lindbo, H Ding, M Altai, J Garousi, A Orlova, V Tolmachev, ... International Journal of Oncology 55 (1), 309-319, 2019 | 16 | 2019 |
| Influence of the N-terminal composition on targeting properties of radiometal-labeled anti-HER2 scaffold protein ADAPT6 J Garousi, S Lindbo, H Honarvar, J Velletta, B Mitran, M Altai, A Orlova, ... Bioconjugate chemistry 27 (11), 2678-2688, 2016 | 15 | 2016 |
| Investigating affinity-maturation strategies and reproducibility of fluorescence-activated cell sorting using a recombinant ADAPT library displayed on staphylococci M Åstrand, J Nilvebrant, M Björnmalm, S Lindbo, S Hober, J Löfblom Protein Engineering, Design and Selection 29 (5), 187-195, 2016 | 9 | 2016 |
| HER2-specific Pseudomonas exotoxin A PE25 based fusions: Influence of targeting domain on target binding, toxicity, and in vivo biodistribution H Ding, M Altai, W Yin, S Lindbo, H Liu, J Garousi, T Xu, A Orlova, ... Pharmaceutics 12 (4), 391, 2020 | 7 | 2020 |
